[1] ZHENG R S, CHEN R, HAN B F, et al. Cancer incidence and mortality in China, 2022[J]. Zhonghua Zhong Liu Za Zhi, 2024, 46(3):221-231.
[2] RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6):1598-1606.
[3] TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. CA A Cancer J Clin, 2015, 65(2):87-108. doi:  10.3322/caac.21262
[4] SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023[J]. CA A Cancer J Clin, 2023, 73(1):17-48.
[5] BROWN Z J, TSILIMIGRAS D I, RUFF S M, et al. Management of hepatocellular carcinoma: a review[J]. JAMA Surg, 2023, 158(4):410-420.
[6] GILLES H, GARBUTT T, LANDRUM J. Hepatocellular carcinoma[J]. Crit Care Nurs Clin N Am, 2022, 34(3):289-301. doi:  10.1016/j.cnc.2022.04.004
[7] 张虎平, 马艳品. 八宝丹胶囊联合替诺福韦治疗乙型病毒性肝炎的临床研究[J]. 临床医学工程, 2021, 28(9):1221-1222. doi:  10.3969/j.issn.1674-4659.2021.09.1221
[8] 任军帮, 沈有秀, 张永刚, 等. 八宝丹胶囊治疗急性胆囊炎患者的临床研究[J]. 中国临床药理学杂志, 2023, 39(12):1689-1693.
[9] 胡玮晔, 高司成, 朱小涵, 等. 八宝丹治疗肝脏疾病的临床与基础研究[J]. 中西医结合肝病杂志, 2023, 33(3):281-283. doi:  10.3969/j.issn.1005-0264.2023.003.024
[10] 徐意, 李伟, 楼妙姿, 等. 八宝丹胶囊治疗原发性肝癌化疗栓塞术后综合征临床研究[J]. 新中医, 2020, 52(16):104-106.
[11] LIANG L, YANG X, YU Y, et al. Babao Dan attenuates hepatic fibrosis by inhibiting hepatic stellate cells activation and proli-feration via TLR4 signaling pathway[J]. Oncotarget, 2016, 7(50):82554-82566.
[12] SCHULIEN I, HASSELBLATT P. Diethylnitrosamine-induced liver tumorigenesis in mice[J]. Methods Cell Biol, 2021, 163:137-152.
[13] HOU J J, ZHANG H Y, SUN B C, et al. The immunobiology of hepatocellular carcinoma in humans and mice: basic concepts and therapeutic implications[J]. J Hepatol, 2020, 72(1):167-182. doi:  10.1016/j.jhep.2019.08.014
[14] HU K R, LI C J, YU T J, et al. Global analysis of qualitative and quantitative metabolism of Notoginsenoside R1 in rat liver-brain-gut axis based on LC-IT-TOF/MS combing mMDF strategy[J]. Phytomedicine, 2022, 104:154261. doi:  10.1016/j.phymed.2022.154261
[15] SEEHAWER M, HEINZMANN F, D’ARTISTA L, et al. Necroptosis microenvironment directs lineage commitment in liver cancer[J]. Nature, 2018, 562(7725):69-75.
[16] ZUCMAN-ROSSI J, VILLANUEVA A, NAULT J C, et al. Genetic landscape and biomarkers of hepatocellular carcinoma[J]. Gastroenterology, 2015, 149(5): 1226-1239.
[17] LEONE V, ALI A, WEBER A, et al. Liver inflammation and hepatobiliary cancers[J]. Trends Cancer, 2021, 7(7):606-623. doi:  10.1016/j.trecan.2021.01.012
[18] TO J C, CHIU A P, TSCHIDA B R, et al. ZBTB20 regulates WNT/CTNNB1 signalling pathway by suppressing PPARG during hepatocellular carcinoma tumourigenesis[J]. JHEP Rep, 2021, 3(2):100223.
[19] XIAO Y, LIU G D, SUN Y, et al. Targeting the estrogen receptor alpha(ERα)-mediated circ-SMG1.72/miR-141-3p/Gelsolin signaling to better suppress the HCC cell invasion[J]. Oncogene, 2020, 39:2493-2508. doi:  10.1038/s41388-019-1150-6
[20] Qu C, He L, Yao N, et al. Myofibroblast-specific Msi2 knockout inhibits HCC progression in a mouse model[J]. Hepatology, 2021, 74(1):458-473. doi:  10.1002/hep.31754